MedTrace Logo

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2024-06-13

Study results available
· View outcomes & findings →

Summary

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

Conditions

Interventions

DRUG

ADCT-301

intravenous infusion

BIOLOGICAL

Pembrolizumab

intravenous infusion

Sponsors & Collaborators

  • ADC Therapeutics S.A.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2022-12-14
Completion
2022-12-14
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03621982 on ClinicalTrials.gov